Skip to content

Clinical trials

Myeloproliferative Disorders trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myeloproliferative Disorders Country / region: Canada Clear all

58 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20042
20051
20061
20074
20092
20101
20112
20122
20132
20145
20154
20161
20171
20181
20193
20204
20215
20223
20233
20243
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed23
Active, not recruiting12
Terminated11
Recruiting10
Not yet recruiting1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Incyte Corporation7
Novartis Pharmaceuticals6
Children's Oncology Group5
National Cancer Institute (NCI)5
Celgene3
PharmaEssentia3
University Health Network, Toronto3
Sierra Oncology LLC - a GSK company2
University of Manitoba2
Alliance for Clinical Trials in Oncology1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myeloproliferative Disorders58
Primary Myelofibrosis25
Myelodysplastic Syndromes19
Thrombocythemia, Essential15
Leukemia, Myeloid, Acute14
Polycythemia Vera13
Hematologic Diseases12
Leukemia, Myelomonocytic, Chronic12
Leukemia11
Bone Marrow Diseases9

Trials

Showing 76 to 58 of 58. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.